Clinical Study Evaluating the Effect of Pentoxifylline as Anti Inflammatory in Patients With Rheumatoid Arthritis

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

Rheumatoid arthritis (RA) is a long-term inflammatory condition that leads to gradual damage of joints lined by synovial membranes, along with various potential effects outside of the joints. While RA can affect any joint, it typically involves the metacarpophalangeal, proximal interphalangeal, and metatarsophalangeal joints, as well as the wrists and knees. Symptoms related to the joints and surrounding tissues include swelling, tenderness upon touch, morning stiffness, and significant difficulty moving the affected joints

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 70
Healthy Volunteers: f
View:

• Patients with active rheumatoid arthritis (not in remission) according to American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) \[9\] i.e., 28 joints disease activity score (DAS 28) \>2.6.

• Patients receiving the conventional DMARDs.

• Both sexes.

• Age range between 18and 70 years old

Locations
Other Locations
Egypt
Faculty of Medicine, Al-Azhar University
RECRUITING
Damietta
Time Frame
Start Date: 2025-06-02
Estimated Completion Date: 2026-09-30
Participants
Target number of participants: 50
Treatments
Active_comparator: Control group
will receive the traditional therapy of RA for three months.
Active_comparator: Pentoxifylline group
will receive 400 mg pentoxifylline two times daily plus the traditional therapy of RA for three months.
Sponsors
Leads: Tanta University
Collaborators: Prof. Sahar Kamal Hegazy, Professor of Clinical Pharmacy, Faculty of Pharmacy - Tanta University, Dr. Mustafa Adel Mustafa Elmenawy Lecturer of Rheumatology and Rehabilitation, Faculty of Medicine - El-Azhar University - Damietta

This content was sourced from clinicaltrials.gov